#1 Clinical Trials Search in Europe

Nilutamide

Nilutamide is an antiandrogen medication that has been studied in several clinical trials for the treatment of prostate cancer. This article summarizes key information about clinical trials investigating nilutamide, either alone or in combination with other therapies, for various stages of prostate cancer. The trials examine nilutamide’s efficacy, safety, and potential benefits compared to other treatment approaches.

Table of Contents

What is Nilutamide?

Nilutamide is a medication primarily used in the treatment of prostate cancer. It belongs to a class of drugs known as antiandrogens, which work by blocking the effects of male hormones (androgens) in the body. Nilutamide is also known by its brand names Anandron and Nilandron[1][2].

How Nilutamide Works

Nilutamide works by blocking the action of androgens, particularly testosterone, on prostate cancer cells. Androgens can stimulate the growth of prostate cancer cells, so by blocking their effects, nilutamide helps to slow down or stop the growth of these cancer cells[3].

Conditions Treated with Nilutamide

Nilutamide is primarily used to treat:

  • Prostate Cancer: Specifically, it is often used in cases of advanced or metastatic prostate cancer (cancer that has spread to other parts of the body)[3].
  • Castration-Resistant Prostate Cancer (CRPC): This is a form of prostate cancer that continues to progress despite low levels of testosterone in the body[3].

How Nilutamide is Administered

Nilutamide is typically taken orally (by mouth) in the form of tablets. The dosage and frequency can vary depending on the specific treatment plan, but common regimens include:

  • Daily dosing[4]
  • Three times daily for the first month, then once daily thereafter[5]

It’s important to take nilutamide exactly as prescribed by your healthcare provider.

Nilutamide in Combination Therapies

Nilutamide is often used as part of a combination therapy approach. Some common combinations include:

  • With LHRH Agonists: Nilutamide may be used alongside drugs like leuprolide acetate or goserelin acetate, which reduce testosterone production in the body[5].
  • With Orchiectomy: Nilutamide can be used after surgical removal of the testicles (orchiectomy) to provide complete androgen blockade[4].
  • With Radiation Therapy: In some cases, nilutamide may be used in combination with radiation therapy for prostate cancer treatment[6].

Nilutamide in Clinical Trials

Nilutamide has been and continues to be studied in various clinical trials to better understand its effectiveness and potential new applications. Some areas of research include:

  • Comparison with Other Antiandrogens: Studies have compared nilutamide to other antiandrogen drugs like bicalutamide and flutamide[4].
  • Use in Early-Stage Prostate Cancer: Some trials are exploring the use of nilutamide in earlier stages of prostate cancer[6].
  • Combination with New Therapies: Researchers are investigating nilutamide in combination with newer prostate cancer treatments[1].

Potential Side Effects

Like all medications, nilutamide can cause side effects. Some potential side effects include:

  • Hot flashes
  • Nausea
  • Fatigue
  • Liver function changes
  • Visual disturbances, particularly difficulty adapting to darkness

It’s important to discuss potential side effects with your healthcare provider and report any unusual symptoms you experience while taking nilutamide[7].

Aspect Details
Study Types Phase I, II, and III randomized clinical trials
Cancer Types Various stages of prostate cancer, including metastatic and castration-resistant
Treatment Approaches Nilutamide as monotherapy, combined with other antiandrogens, in combination with radiotherapy, or as part of chemohormonal therapy
Comparison Treatments Other antiandrogens (e.g., bicalutamide, flutamide), LHRH analogs, chemotherapy drugs (e.g., docetaxel)
Primary Outcomes Overall survival, progression-free survival, PSA response, time to hormone resistance
Secondary Outcomes Quality of life, toxicity profile, testosterone recovery, time to PSA progression
Administration Typically oral, once daily dosing
Trial Durations Varied, ranging from several months to multiple years of follow-up

FAQ

  • What is nilutamide and how does it work? Nilutamide is an antiandrogen medication that works by blocking the effects of androgens (male hormones) like testosterone on prostate cancer cells. By preventing androgens from stimulating cancer growth, nilutamide can help slow or stop the progression of prostate cancer.
  • In which types of prostate cancer is nilutamide being studied? Clinical trials are investigating nilutamide for various stages of prostate cancer, including locally advanced, metastatic, and castration-resistant prostate cancer. It is being studied both as a standalone treatment and in combination with other therapies.
  • How is nilutamide typically administered in clinical trials? In most trials, nilutamide is given orally (by mouth) once daily. The exact dosage and duration can vary between studies. It is often used as part of a combination therapy approach, frequently alongside other hormonal treatments or chemotherapy drugs.
  • What are some potential side effects of nilutamide? While specific side effects are not detailed in the trial summaries, common side effects of antiandrogen medications like nilutamide can include hot flashes, fatigue, nausea, and changes in liver function. It's important to note that clinical trials closely monitor patients for any adverse effects.
  • How does nilutamide compare to other prostate cancer treatments in trials? Several trials are comparing nilutamide to other treatments or using it in combination therapies. For example, some studies compare nilutamide to other antiandrogens or evaluate its effectiveness when combined with radiation therapy or chemotherapy drugs like docetaxel. The goal is to determine if nilutamide offers any advantages in terms of efficacy or side effect profile compared to existing treatments.

Ongoing Clinical Trials on Nilutamide

  • Study on Enzalutamide and Drug Combination for High-Risk Localized Prostate Cancer Patients

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Ireland Spain

  • Study Comparing 177Lu-PSMA-617 with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +4

Glossary

  • Androgen: Male hormones, such as testosterone, that can stimulate the growth of prostate cancer cells.
  • Antiandrogen: A type of medication that blocks the effects of androgens on cancer cells, helping to slow or stop prostate cancer growth.
  • Castration-resistant prostate cancer: A form of prostate cancer that continues to grow even when the level of testosterone in the body is reduced to very low levels.
  • Hormone therapy: Treatment that adds, blocks, or removes hormones to slow or stop the growth of cancer cells that need hormones to grow.
  • Metastatic prostate cancer: Cancer that has spread from the prostate to other parts of the body.
  • Prostate-specific antigen (PSA): A protein produced by the prostate gland. Elevated PSA levels may indicate prostate cancer or other prostate conditions.
  • Radical prostatectomy: Surgical removal of the entire prostate gland and some surrounding tissue.
  • Radiotherapy: The use of high-energy radiation to kill cancer cells and shrink tumors.
  • Biochemical failure: A rise in PSA levels after treatment, which may indicate cancer recurrence.
  • Luteinizing hormone-releasing hormone (LHRH) analog: A type of hormone therapy that reduces testosterone production in the body.

References

  1. https://clinicaltrials.gov/study/NCT00512668
  2. https://clinicaltrials.gov/study/NCT01786265
  3. https://clinicaltrials.gov/study/NCT00918385
  4. https://clinicaltrials.gov/study/NCT00002633
  5. https://clinicaltrials.gov/study/NCT00003653
  6. https://clinicaltrials.gov/study/NCT03070886
  7. https://clinicaltrials.gov/study/NCT00020254